Trial Profile
A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Pertuzumab; Trastuzumab
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms G7; GeparSepto
- 11 Jul 2023 Results (n=279) assessing the prognostic and predictive potential of CAV1/2 expression for early-stage HER2-negative breast cancer patients receiving neoadjuvant paclitaxel-based chemotherapy regimens, published in the Clinical Cancer Research.
- 04 Apr 2023 Results (n=279 of HER2 negative BC patients) assessing immune-cell activity of BC tumors by expression-based analysis to determine if it is prognostic and/or predictive of response to neoadjuvant paclitaxel-based therapy published in the Clinical Cancer Research
- 13 May 2019 Status changed to completed as per results published in the Journal of Clinical Oncology